{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.8","value":"2.8"},{"groupId":"OG001","spread":"0.8","value":"2.0"}]}],"title":"30 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.8","value":"3.1"},{"groupId":"OG001","spread":"0.8","value":"2.2"}]}],"title":"60 minutes"}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"Global evaluation of the study medication was assessed by the participant on a 5-point scale (1=Poor, 2=Fair, 3=Good, 4=Very good, 5=Excellent) at 30 and 60 minutes after each dose of study medication during each breakthrough pain episode. A higher score indicates a better evaluation.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received fentanyl sublingual spray 7 times randomly (out of 10 treatments total) to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.","id":"OG000","title":"Fentanyl Sublingual Spray"},{"description":"Participants received placebo 3 times randomly (out of 10 treatments total) to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Intent-to-treat (ITT) population: All participants in the double-blind treatment period who received at least 1 dose of study medication and had at least 1 pain measurement. 4 of the 96 participants in the ITT population were excluded from analysis because they did not have at least 1 dose of study medication and 1 dose of placebo.","reportingStatus":"POSTED","timeFrame":"30 through 60 minutes after dosing for each pain episode","title":"Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing","type":"SECONDARY","unitOfMeasure":"Units on a scale"}